Puma Biotechnology Inc PBYI:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 06/24/22 EDT
2.99quote price arrow up+0.14 (+4.91%)
Volume
547,634
Close
2.85quote price arrow down-0.05 (-1.72%)
Volume
3,677,380
52 week range
1.60 - 9.77
Loading...
  • Open2.95
  • Day High3.13
  • Day Low2.81
  • Prev Close2.90
  • 52 Week High9.77
  • 52 Week High Date06/28/21
  • 52 Week Low1.60
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap128.16M
  • Shares Out44.97M
  • 10 Day Average Volume0.55M
  • Dividend-
  • Dividend Yield-
  • Beta0.66
  • YTD % Change-6.25

KEY STATS

  • Open2.95
  • Day High3.13
  • Day Low2.81
  • Prev Close2.90
  • 52 Week High9.77
  • 52 Week High Date06/28/21
  • 52 Week Low1.60
  • 52 Week Low Date05/12/22
  • Market Cap128.16M
  • Shares Out44.97M
  • 10 Day Average Volume0.55M
  • Dividend-
  • Dividend Yield-
  • Beta0.66
  • YTD % Change-6.25

RATIOS/PROFITABILITY

  • EPS (TTM)-1.20
  • P/E (TTM)-2.38
  • Fwd P/E (NTM)114.00
  • EBITDA (TTM)-9.593M
  • ROE (TTM)-415.21%
  • Revenue (TTM)200.72M
  • Gross Margin (TTM)77.59%
  • Net Margin (TTM)-24.39%
  • Debt To Equity (MRQ)1,362.93%

EVENTS

  • Earnings Date08/03/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Puma Biotechnology Inc

Profile

MORE
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, which is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2 and HER4. It is primarily focused on the development and commercialization of the oral version...
Alan Auerbach
Chairman of the Board, President, Chief Executive Officer, Secretary
Maximo Nougues
Chief Financial Officer
Address
SUITE 2150, 10880 WILSHIRE BLVD.
Los Angeles, CA
90024
United States

Top Peers

SYMBOLLASTCHG%CHG
AKBA
Akebia Therapeutics Inc
0.3652-0.028-7.1211%
CLVS
Clovis Oncology Inc
1.70-0.04-2.30%
HBIO
Harvard Bioscience Inc
3.82+0.23+6.41%
SELB
Selecta Biosciences Inc
1.33-0.07-5.00%
MCRB
Seres Therapeutics Inc
3.38-0.03-0.88%